Arcus Biosciences and partner Gilead announced that an independent data monitoring committee recommended stopping a Phase 3 trial of the anti-TIGIT antibody domvanalimab for futility in upper gastrointestinal cancers. Interim analyses showed the domvanalimab-based combination did not improve overall survival versus the Opdivo-plus-chemotherapy control arm. The companies will discontinue the domvanalimab program in that indication and reallocate resources to other pipeline assets.